Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with Erb~B2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

摘要

The inhibitory effect of trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of ErbB2, is associated with its ability to induce ErbB2-Y1248 phosphorylation, and the status of phosphorylated ErbB2-Y1248 (ErbB2-pY1248) may correlate with the sensitivity of breast cancers to trastuzumab. The mechanisms of which remain unclear. Here, we show that binding of trastuzumab to ErbB2 activates ErbB2 kinase activity and enhances ErbB2-Y1248 phosphorylation in trastuzumab-sensitive breast cancer cells. This in turn increases the interaction between ErbB2 and non-receptor Csk-homologous kinase (CHK), leading to growth inhibition of breast cancer ceils. Overexpression of CHK mimics trastuzumab treatment to: mediate ErbB2-Yi248 phosphorylation, Akt downregulation, and growth inhibition of trastuzumab-sensitive breast cancer cells. CHK overexpression combined with trastuzumab exerts an additive effect on eel! growth inhibition. We further demonstrate that positive ErbB2-pYi248 staining in ErbB2-positive breast cancer biop-sies: correlates with the increased trastuzumab response in trastuzumab neoadjuvant settings. Collectively, this study highlights an important rote forErbB2-pY1248 in mediating trastuzumab-induced growth inhibition and trastuzumab-induced interactions between CHK and ErbB2-pY1248 is identified as a novel mechanism of action that mediates the growth inhibition of breast cancer celts. The novel mechanistic insights into trastuzumab action revealed by this study may impact the design of next generation of therapeutic monoclonal antibodies targeting receptor tyrbsine kinases, as well as open new avenues to identify novel targets for the treatment of ErbB2-positive cancers.